drugset / Trial / NCT06996886

A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations

NCT06996886

Phase 1 Completed 16 enrolled AstraZeneca Parexel · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the relative bioavailability of a single dose AZD5004 in healthy participants, among 3 different oral tablet formulations.

Timeline

Start
2025-05-22
Primary completion
2025-07-15
Completion
2025-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5004 Unknown Oral

Indications

No indication recorded.